Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Use of neoadjuvant approaches in breast cancer during the COVID-19 pandemic

Hiroji Iwata • 3 Dec 2021
SABCS 2021
Breast Cancer

Hiroji Iwata, MD, PhD, Aichi Cancer Center Hospital, Nagoya, Japan, provides an overview of neoadjuvant therapy, highlighting the increased use of endocrine therapy during the COVID-19 pandemic. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

More from Hiroji Iwata

5:34
NEOS: prognosis of ER+ breast cancer pts who received neoadjuvant ET with/without adjuvant chemo
Hiroji Iwata • 3 Dec 2021
1:31
Future research directions for ER+ positive breast cancer
Hiroji Iwata • 3 Dec 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals